As previously shown in breast cancer [18], DOT1L inhibition resulted in a dose-dependent inhibition of ESR1 gene expression in both cell lines, as demonstrated by a decrease of both ERα mRNA (Figure 5a) and protein (Figure 5b) levels upon EPZ treatment. Here, DOT1L is linked to breast carcinoma.